Work

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.816.816

Authors: Shaji Kumar, William I Bensinger, Craig B. Reeder, Todd M. Zimmerman, James R. Berenson, Deborah Berg, Guohui Liu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Ruben Niesvizky

Institutions: Mayo Clinic, Fred Hutch Cancer Center, Mayo Clinic in Arizona, University of Chicago, Institute for Myeloma & Bone Cancer Research, Takeda Oncology (United States), Weill Cornell Medicine

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979451615

FWCI: 3.582

Cites:

Cited by: 21

Related to: 10